162 related articles for article (PubMed ID: 32954836)
1. Current and emerging fixed combination therapies in glaucoma: a safety and tolerability review.
Konstas AG; Schmetterer L; Costa VP; Holló G; Katsanos A; Denis P; Quaranta L; Irkec M; Castejón MA; Teus MA; Robin AL
Expert Opin Drug Saf; 2020 Nov; 19(11):1445-1460. PubMed ID: 32954836
[TBL] [Abstract][Full Text] [Related]
2. Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice.
Holló G; Topouzis F; Fechtner RD
Expert Opin Pharmacother; 2014 Aug; 15(12):1737-47. PubMed ID: 24998246
[TBL] [Abstract][Full Text] [Related]
3. The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability.
Konstas AG; Labbé A; Katsanos A; Meier-Gibbons F; Irkec M; Boboridis KG; Holló G; García-Feijoo J; Dutton GN; Baudouin C
Expert Opin Drug Saf; 2021 Apr; 20(4):453-466. PubMed ID: 33478284
[No Abstract] [Full Text] [Related]
4. Preservative-free tafluprost/timolol fixed combination: a new opportunity in the treatment of glaucoma.
Konstas AG; Holló G
Expert Opin Pharmacother; 2016 Jun; 17(9):1271-83. PubMed ID: 27123557
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of tafluprost 0.0015% and timolol maleate 0.5% fixed combination in patients with ocular hypertension or open-angle glaucoma.
Lorenz K; Pfeiffer N
Expert Opin Pharmacother; 2014 Oct; 15(15):2255-62. PubMed ID: 25170534
[TBL] [Abstract][Full Text] [Related]
6. Safety and tolerability of the tafluprost/timolol fixed combination for the treatment of glaucoma.
Holló G; Katsanos A
Expert Opin Drug Saf; 2015 Apr; 14(4):609-17. PubMed ID: 25640746
[TBL] [Abstract][Full Text] [Related]
7. Role of fixed combinations in the management of open-angle glaucoma.
Hommer A
Expert Rev Pharmacoecon Outcomes Res; 2011 Feb; 11(1):91-9. PubMed ID: 21351861
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of preservative-free eye drops containing a fixed combination of dorzolamide and timolol in glaucoma patients.
Renieri G; Führer K; Scheithe K; Lorenz K; Pfeiffer N; Thieme H
J Ocul Pharmacol Ther; 2010 Dec; 26(6):597-603. PubMed ID: 20977366
[TBL] [Abstract][Full Text] [Related]
9. A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension.
Hughes BA; Bacharach J; Craven ER; Kaback MB; Mallick S; Landry TA; Bergamini MV
J Glaucoma; 2005 Oct; 14(5):392-9. PubMed ID: 16148589
[TBL] [Abstract][Full Text] [Related]
10. Latanoprost/timolol fixed combination for the treatment of glaucoma.
Konstas AG; Mocan MC; Katsanos A; Voudouragkaki IC; Irkec M
Expert Opin Pharmacother; 2013 Sep; 14(13):1815-27. PubMed ID: 23806084
[TBL] [Abstract][Full Text] [Related]
11. A 6-month study comparing efficacy, safety, and tolerability of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% versus each of its individual preservative-free components.
Pfeiffer N; Traverso CE; Lorenz K; Saarela V; Liinamaa J; Uusitalo H; Astakhov Y; Boiko E; Ropo A;
Adv Ther; 2014 Dec; 31(12):1228-46. PubMed ID: 25447269
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of prostaglandin-timolol fixed combinations: an updated systematic review and meta-analysis.
Lou H; Wang H; Zong Y; Cheng JW; Wei RL
Curr Med Res Opin; 2015 Jun; 31(6):1139-47. PubMed ID: 25867658
[TBL] [Abstract][Full Text] [Related]
13. [Combination therapy in the medical treatment of glaucoma].
Hommer A
Klin Monbl Augenheilkd; 2013 Feb; 230(2):133-40. PubMed ID: 23335083
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of prostaglandin-timolol fixed combinations: a meta-analysis of randomized clinical trials.
Aptel F; Cucherat M; Denis P
Eur J Ophthalmol; 2012; 22(1):5-18. PubMed ID: 22167538
[TBL] [Abstract][Full Text] [Related]
15. Switching from latanoprost to fixed-combination latanoprost-timolol: a 21-day, randomized, double-masked, active-control study in patients with glaucoma and ocular hypertension.
Olander K; Zimmerman TJ; Downes N; Schoenfelder J;
Clin Ther; 2004 Oct; 26(10):1619-29. PubMed ID: 15598478
[TBL] [Abstract][Full Text] [Related]
16. Noninferiority of Preservative-free Versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients With Open-angle Glaucoma or Ocular Hypertension.
Aptel F; Pfeiffer N; Schmickler S; Clarke J; Lavín-Dapena C; Moreno-Montañés J; Żarnowski T; Csutak A; Jugaste T; Volksone L; Astakhov YS; Coupier L; Nordmann JP; Stalmans I;
J Glaucoma; 2019 Jun; 28(6):498-506. PubMed ID: 31166287
[TBL] [Abstract][Full Text] [Related]
17. IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma.
Hommer A; Mohammed Ramez O; Burchert M; Kimmich F
Curr Med Res Opin; 2010 Aug; 26(8):1905-13. PubMed ID: 20553122
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of the fixed combination of latanoprost and timolol versus other fixed combinations for primary open-angle glaucoma and ocular hypertension: A systematic review and meta-analysis.
Xing Y; Zhu L; Zhang K; Huang S
PLoS One; 2020; 15(2):e0229682. PubMed ID: 32106236
[TBL] [Abstract][Full Text] [Related]
19. Fixed-combination brimonidine-timolol versus latanoprost in glaucoma and ocular hypertension: a 12-week, randomized, comparison study.
Katz LJ; Rauchman SH; Cottingham AJ; Simmons ST; Williams JM; Schiffman RM; Hollander DA
Curr Med Res Opin; 2012 May; 28(5):781-8. PubMed ID: 22458918
[TBL] [Abstract][Full Text] [Related]
20. Travoprost/timolol fixed combination in the management of open-angle glaucoma: a clinical review.
Denis P
Expert Opin Pharmacother; 2011 Feb; 12(3):463-71. PubMed ID: 21254951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]